Barclays Maintains Overweight on Janux Therapeutics, Raises Price Target to $48
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and raises the price target from $47 to $48.
Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and raises the price target from $47 to $48.